Preclinical Toxicology of New Drugs.
Abstract
Preclinical toxicology studies of WR238605, Succinate and Pyridostigmine Bromide are being performed to assist the U.S. Army Medical R&D Command (USAMRDC) in its decision of whether or not to allow widespread clinical use of these agents. Subacute (28 day) toxicity studies of WR238605, Succinate, a potential antimalarial agent, were conducted in rats and dogs. Toxicity studies to define the reversibility of pyridostigmine-induced changes in the morphology of the neuromuscular junction were conducted in rats. Additionally, subacute (14 day) toxicity studies of pyridostigmine, a reversible anticholinesterase inhibitor, were conducted in rats and dogs. Results of these studies are detailed in individual study reports. Briefly, oral doses of WR238605, Succinate produced methemoglobin formation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 04, 1986
- Accession Number
- ADA166877
Entities
People
- J. G. Page
Organizations
- Battelle Memorial Institute